Expert Consultations: Real-World Answers

The Clinical Guide to Sleep Issues in Psychiatry – Interview

Published on July 1, 2021 Expired on April 1, 2025

Guest

Mohan Gautam

To unlock this audio you need to become a Silver, Gold, Silver extended or Gold extended Member.

Check Our CME Program

Downloads for Offline Access

Download Audio File (MP3)

Interview Highlights

For patients with insomnia, it is essential to take a good history, which includes the medical and psychiatric history, lifestyle, and recent life events.
Whereas controlled substances, such as benzodiazepines, do play a role in the management of acute insomnia, they should be used only on a short-term basis.
In cases of persistent insomnia, it is recommended that patients be engaged in a discussion about insomnia disorder and referred for formal sleep laboratory evaluations, such as polysomnography testing.

Text Version

This edition of Psychopharmacology Institute’s Expert Consultations features Charles Reynolds III, M.D., who is a professor emeritus of psychiatry at the University of Pittsburgh School of Medicine. Dr. Reynolds was the Chair of the DSM-5 Work Group on Sleep–Wake Disorders. In this interview, we will discuss the

Unlock this Expert Consultation and earn 0.50 CMEs
Become a Silver, Gold, Silver extended or Gold extended Member.

Get Instant Access

Already have an account? Sign in

Learning Objectives:

After completing this activity, the learner will be able to:

Identify medical and lifestyle factors that should be assessed in patients with insomnia.
Discuss appropriate use of benzodiazepines and Z-drugs among patients with insomnia complaints.
Assess the utility of mirtazapine, modafinil, trazodone, and doxepin for the treatment of patients with insomnia.

Original Release Date: 07/01/2021

Review and Re-release Date: 03/01/2024

Expiration Date: 04/01/2025

Expert: Charles Reynolds, M.D.

Medical Editors: Mohan Gautam, M.D., Lorena Rodriguez, M.D.

Relevant Financial Disclosures:

None of the faculty, planners, and reviewers for this educational activity have relevant financial relationship(s) to disclose during the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Contact Information: For questions regarding the content or access to this activity, contact us at support@psychopharmacologyinstitute.com

Instructions for Participation and Credit:

Participants must complete the activity online during the valid credit period that is noted above.

Follow these steps to earn CME credit:

View the required educational content provided on this course page.
Answer the quiz for promoting retention of knowledge.
Complete the Post Activity Evaluation for providing the necessary feedback for continuing accreditation purposes and for the development of future activities. NOTE: Completing the Post Activity Evaluation after the quiz is required to receive the earned credit.
Download your certificate.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

Medical Academy designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Charles F. Reynolds III, M.D.